| dbo:abstract |
Lofexidine, sold under the brand name Lucemyra among others, is a medication historically used to treat high blood pressure; today, it is more commonly used to help with the physical symptoms of opioid withdrawal. It is taken by mouth. It is an α2A adrenergic receptor agonist. It was approved for use by the Food and Drug Administration in the United States in 2018. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. (en) La lofexidina è un farmaco con proprietà simili a quelle della clonidina. Si tratta cioè di un agonista del recettore alfa 2 adrenergico. Secondo alcuni studi i due farmaci avrebbero dimostrato una efficacia sostanzialmente sovrapponibile nel trattamento dell'ipertensione sia di grado lieve che moderato. La lofexidina godrebbe del vantaggio di presentare un minor effetto sedativo. Storicamente la lofexidina è stata utilizzata come anti ipertensivo a breve durata d'azione, ma ha conosciuto un maggiore successo nel trattamento volto ad alleviare i sintomi fisici di astinenza da eroina ed oppiacei. (it) Lofeksydyna (łac. lofexidinum) – organiczny związek chemiczny zawierający resztę 2,6-dichlorofenolu połączoną mostkiem eterowym z resztą 2-etylo-2-imidazoliny. (pl) |
| dbo:alternativeName |
Britlofex, Lucemyra, Kai Er Ding, others (en) |
| dbo:casNumber |
31036-80-3 |
| dbo:chEBI |
51368 |
| dbo:chEMBL |
17860 |
| dbo:drugbank |
DB04948 |
| dbo:fdaUniiCode |
UI82K0T627 |
| dbo:kegg |
D08141 |
| dbo:pubchem |
30668 |
| dbo:thumbnail |
wiki-commons:Special:FilePath/Lofexidine.svg?width=300 |
| dbo:wikiPageID |
6553564 (xsd:integer) |
| dbo:wikiPageLength |
15124 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1096292039 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Pramipexole dbr:Pregnancy dbr:Bradycardia dbr:Breastfeeding dbr:Arene_substitution_pattern dbr:Hydrochlorothiazide dbr:Hypertension dbr:Hypokalemia dbr:United_Kingdom dbr:United_States dbr:Racemic_mixture dbc:Alpha-2_adrenergic_receptor_agonists dbc:Chloroarenes dbc:Imidazolines dbc:Phenol_ethers dbr:Medical_prescription dbr:Melting_point dbr:Opioid_use_disorder dbr:Oral_administration dbr:Citalopram dbr:Clobazam dbr:Clonidine dbr:Endogenous_opioid dbr:Gabapentin dbr:Naltrexone dbr:Theophylline dbr:Opioid_withdrawal dbr:Levetiracetam dbr:Liver dbr:Losartan dbr:Hot_flash dbr:Buprenorphine dbr:Torsade_de_pointes dbr:Dissociation_constant dbr:Drug_detoxification dbr:Drug_interaction dbr:Craving_(withdrawal) dbr:Adrenergic_receptor dbr:Amiodarone dbr:Alpha-2A_adrenergic_receptor dbr:FDA dbr:Fluconazole dbr:Food_and_Drug_Administration dbr:Norepinephrine dbr:Central_nervous_system dbr:Chronic_kidney_disease dbr:Glucuronidation dbr:QT_interval dbr:Half-life dbr:High_blood_pressure dbr:Ataxia dbr:Hydrochloride dbr:Hypotension dbc:Antihypertensive_agents dbr:Chlorine dbr:Kidney dbr:Bioavailability dbr:Tablet_(pharmacy) dbr:Cmax_(pharmacology) dbr:Dexamethasone dbr:Dizziness dbr:Methadone dbr:Metoprolol dbr:National_Institute_for_Health_and_Care_Excellence dbr:Imidazoline dbr:First-in-class_medication dbr:Somnolence dbr:Xerostomia dbr:Phenyl dbr:QT_prolongation dbr:Alcohol_withdrawal dbr:Plasma_protein_bound dbr:Rebound_hypertension dbr:US_WorldMeds dbr:File:Clonidine_and_lofexidine.svg |
| dbp:atcPrefix |
N07 (en) |
| dbp:atcSuffix |
BC04 (en) |
| dbp:bioavailability |
>90% (en) |
| dbp:c |
11 (xsd:integer) |
| dbp:casNumber |
31036 (xsd:integer) |
| dbp:chebi |
51368 (xsd:integer) |
| dbp:chembl |
17860 (xsd:integer) |
| dbp:chemspiderid |
28460 (xsd:integer) |
| dbp:chirality |
dbr:Racemic_mixture |
| dbp:cl |
2 (xsd:integer) |
| dbp:drugbank |
DB04948 (en) |
| dbp:eliminationHalfLife |
39600.0 |
| dbp:excretion |
dbr:Kidney |
| dbp:h |
12 (xsd:integer) |
| dbp:iupacName |
-2 (xsd:integer) |
| dbp:kegg |
D08141 (en) |
| dbp:legalAu |
S4 (en) |
| dbp:legalStatus |
Rx-only (en) |
| dbp:legalUk |
POM (en) |
| dbp:legalUs |
Rx-only (en) |
| dbp:metabolism |
Liver (en) |
| dbp:n |
2 (xsd:integer) |
| dbp:o |
1 (xsd:integer) |
| dbp:pregnancyUs |
N (en) |
| dbp:proteinBound |
80 (xsd:integer) |
| dbp:pubchem |
30668 (xsd:integer) |
| dbp:routesOfAdministration |
By mouth (en) |
| dbp:smiles |
Clc2ccccc2 (en) |
| dbp:stdinchi |
1 (xsd:integer) |
| dbp:stdinchikey |
KSMAGQUYOIHWFS-UHFFFAOYSA-N (en) |
| dbp:tradename |
Britlofex, Lucemyra, Kai Er Ding, others (en) |
| dbp:unii |
UI82K0T627 (en) |
| dbp:verifiedfields |
changed (en) |
| dbp:verifiedrevid |
408579887 (xsd:integer) |
| dbp:width |
175 (xsd:integer) |
| dbp:wikiPageUsesTemplate |
dbt:Adrenergic_receptor_modulators dbt:Citation_needed dbt:Drugbox dbt:LD50 dbt:Reflist dbt:Short_description dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Ebicite dbt:Fdacite dbt:Keggcite dbt:Stdinchicite dbt:Antihypertensives_and_diuretics dbt:Drugs.com dbt:Antiaddictives |
| dcterms:subject |
dbc:Alpha-2_adrenergic_receptor_agonists dbc:Chloroarenes dbc:Imidazolines dbc:Phenol_ethers dbc:Antihypertensive_agents |
| gold:hypernym |
dbr:Α |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:WikicatMolecularFormulas yago:Abstraction100002137 yago:Communication100033020 yago:Element114840755 yago:Formula106816935 yago:Matter100020827 yago:Message106598915 yago:MolecularFormula106817173 yago:Part113809207 yago:PhysicalEntity100001930 yago:Quintessence114847103 yago:Relation100031921 dbo:Drug yago:Statement106722453 yago:Substance100019613 yago:WikicatPhenolEthers umbel-rc:DrugProduct |
| rdfs:comment |
Lofexidine, sold under the brand name Lucemyra among others, is a medication historically used to treat high blood pressure; today, it is more commonly used to help with the physical symptoms of opioid withdrawal. It is taken by mouth. It is an α2A adrenergic receptor agonist. It was approved for use by the Food and Drug Administration in the United States in 2018. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. (en) La lofexidina è un farmaco con proprietà simili a quelle della clonidina. Si tratta cioè di un agonista del recettore alfa 2 adrenergico. Secondo alcuni studi i due farmaci avrebbero dimostrato una efficacia sostanzialmente sovrapponibile nel trattamento dell'ipertensione sia di grado lieve che moderato. La lofexidina godrebbe del vantaggio di presentare un minor effetto sedativo. Storicamente la lofexidina è stata utilizzata come anti ipertensivo a breve durata d'azione, ma ha conosciuto un maggiore successo nel trattamento volto ad alleviare i sintomi fisici di astinenza da eroina ed oppiacei. (it) Lofeksydyna (łac. lofexidinum) – organiczny związek chemiczny zawierający resztę 2,6-dichlorofenolu połączoną mostkiem eterowym z resztą 2-etylo-2-imidazoliny. (pl) |
| rdfs:label |
Lofexidina (it) Lofexidine (en) Lofeksydyna (pl) |
| owl:sameAs |
freebase:Lofexidine http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04948 yago-res:Lofexidine wikidata:Lofexidine dbpedia-fa:Lofexidine dbpedia-it:Lofexidine dbpedia-pl:Lofexidine dbpedia-sh:Lofexidine dbpedia-sr:Lofexidine dbpedia-vi:Lofexidine https://global.dbpedia.org/id/3YdH7 |
| prov:wasDerivedFrom |
wikipedia-en:Lofexidine?oldid=1096292039&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/Clonidine_and_lofexidine.svg wiki-commons:Special:FilePath/Lofexidine.svg |
| foaf:isPrimaryTopicOf |
wikipedia-en:Lofexidine |
| is dbo:wikiPageRedirects of |
dbr:C11H12Cl2N2O dbr:ATC_code_N07BC04 dbr:ATCvet_code_QN07BC04 dbr:BritLofex dbr:Lucemyra dbr:Britlofex dbr:Lofexidine_hydrochloride |
| is dbo:wikiPageWikiLink of |
dbr:List_of_adrenergic_drugs dbr:Opioid_use_disorder dbr:Opioid_withdrawal dbr:C11H12Cl2N2O dbr:Adrenergic_receptor dbr:Alpha-2A_adrenergic_receptor dbr:Alpha-2_adrenergic_receptor dbr:Alpha-adrenergic_agonist dbr:ATC_code_N07BC04 dbr:ATCvet_code_QN07BC04 dbr:ATC_code_N07 dbr:Effects_of_cannabis dbr:Cannabis_use_disorder dbr:BritLofex dbr:List_of_drugs:_Lo dbr:Lucemyra dbr:Britlofex dbr:Lofexidine_hydrochloride |
| is foaf:primaryTopic of |
wikipedia-en:Lofexidine |
